ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2010

Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases

Rie Karasawa1, Toshiko Sato1, Megumi Tanaka1, Mayumi Tamaki1, Kazuo Yudoh1 and James Jarvis2, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoantibodies, autoantigens, endothelial cells, juvenile dermatomyositis and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Pediatric Rheumatology – Basic Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-endothelial cell antibodies (AECA) are antibodies detected in multiple autoimmune and inflammatory diseases. Increased levels of such antibodies may be involved in disease activity and/or the coexistence of vasculitis. Juvenile dermatomyositis (JDM) shows many pathological features of vasculitis. Many autoantibodies detected in JDM have specific clinical and phenotypic associations, but their relationship to disease pathology remains unclear. Juvenile idiopathic arthritis (JIA) is a heterogeneous group of inflammatory diseases. There are no useful autoantibody biomarkers for diagnosis or for characterization of the disease. We aimed to detect target antigens for AECA and to investigate the roles of AECA in both diseases.

Methods: We screened plasma from pediatric rheumatic diseases (3 children with JDM and 2 children with polyarticular JIA) and from healthy children for the presence of AECA by western blotting and two-dimensional electrophoresis (2DE) using proteins extracted from human aortic endothelial cells (HAEC) as the substrate. Selected antigens were positive only in plasma of children with pediatric rheumatic diseases but not in plasma of healthy children. We performed mass spectrometry to identify the candidate antigens from 2DE gels and used ELISA assays to confirm the presence of specific antibodies.

Results: We successfully identified more than 600 proteins that were candidate targets of AECA in JIA and JDM using proteomics. Among these antigens were proteins regulating cellular redox processes. These included peroxiredoxins (Prxs), a family of related antioxidant enzymes. Using ELISA assays, IgG autoantibodies to Prx2 were detected in 12% of the patients with JDM (n=51) but not in healthy children (n=20). However, 24% of JDM patients with active disease (n=25) had anti-Prx2 antibodies, while these antibodies were absent (p<0.01) in JDM patients with inactive disease (n=26). We also noted that 17% of JIA patients with active disease (n=12) had anti-Prx2 antibodies. There was no difference in the frequency of anti-Prx2 antibodies between JIA patients with active disease and those with inactive disease. Another group of antigens that were detected were tropomyosins, a family of actin filament binding proteins, which are categorized into muscle isoforms and non-muscle isoforms. IgG autoantibodies to tropomyosin beta chain (TPM2) were detected in 24% of the patients with JIA (n=17) in contrast to 5% of healthy children (n=20). Interestingly, IgG autoantibodies to TPM2 were detected in 43% of the untreated JIA patients with active disease (n=7) in contrast to 5% (p<0.05) of healthy children. On the other hand, 15 % of JDM patients (n=20) had anti-TPM2 antibodies.

Conclusion: IgG antibodies to Prx2 and TPM2 in the proteome of HAEC are present in the children with JDM and with JIA. The measurement of anti-Prx2 antibodies might be useful for evaluation of disease activity in JDM.


Disclosure: R. Karasawa, None; T. Sato, None; M. Tanaka, None; M. Tamaki, None; K. Yudoh, None; J. Jarvis, None.

To cite this abstract in AMA style:

Karasawa R, Sato T, Tanaka M, Tamaki M, Yudoh K, Jarvis J. Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/anti-endothelial-cell-antibodies-in-pediatric-rheumatic-diseases/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-endothelial-cell-antibodies-in-pediatric-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.